Early-onset lung cancer

1. PhenoAgeAccel raises the risk of early-onset lung cancer in humans (OR = 1.18; 95% CI: 1.14-1.23).

   “PhenoAgeAccel was associated with a dose-dependent increase in early-onset lung cancer risk (odds ratio [OR] = 1.18; 95% CI: 1.14-1.23).”

   Humans

   Phenotypic age acceleration and early-onset lung cancer: a case-control and prognostic cohort study involving multiple clinical centres with validation in the UK Biobank

   EBioMedicine·10 Feb 2026

More on PhenoAgeAccel